Delta-Fly Pharmaの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2020/10/08 | 2,315 | 2,350 | 2,283 | 2,320 | +32 | +1.4% | 141,000 |
2020/10/07 | 2,249 | 2,290 | 2,204 | 2,288 | +31 | +1.4% | 156,000 |
2020/10/06 | 2,249 | 2,325 | 2,218 | 2,257 | +21 | +0.9% | 216,500 |
2020/10/05 | 2,155 | 2,278 | 2,116 | 2,236 | +128 | +6.1% | 210,200 |
2020/10/02 | 2,199 | 2,237 | 2,095 | 2,108 | - | - | 285,700 |
2020/10/01 | 0 | 0 | 0 | 0 | - | - | 0 |
2020/09/30 | 2,101 | 2,214 | 2,086 | 2,173 | +52 | +2.5% | 225,300 |
2020/09/29 | 2,105 | 2,246 | 2,044 | 2,121 | -6 | -0.3% | 320,700 |
2020/09/28 | 2,386 | 2,418 | 2,002 | 2,127 | -269 | -11.2% | 772,500 |
2020/09/25 | 2,575 | 2,588 | 2,370 | 2,396 | -195 | -7.5% | 446,600 |
2020/09/24 | 2,628 | 2,667 | 2,539 | 2,591 | -70 | -2.6% | 265,900 |
2020/09/23 | 2,699 | 2,740 | 2,613 | 2,661 | +4 | +0.2% | 220,200 |
2020/09/18 | 2,626 | 2,662 | 2,601 | 2,657 | -19 | -0.7% | 175,300 |
2020/09/17 | 2,630 | 2,677 | 2,580 | 2,676 | +44 | +1.7% | 234,900 |
2020/09/16 | 2,591 | 2,655 | 2,557 | 2,632 | +91 | +3.6% | 315,500 |
2020/09/15 | 2,471 | 2,570 | 2,373 | 2,541 | +20 | +0.8% | 466,100 |
2020/09/14 | 2,570 | 2,684 | 2,517 | 2,521 | +9 | +0.4% | 521,800 |
2020/09/11 | 2,373 | 2,535 | 2,305 | 2,512 | +186 | +8% | 424,100 |
2020/09/10 | 2,341 | 2,355 | 2,287 | 2,326 | -4 | -0.2% | 175,500 |
2020/09/09 | 2,265 | 2,368 | 2,254 | 2,330 | +49 | +2.1% | 313,000 |
2020/09/08 | 2,296 | 2,311 | 2,185 | 2,281 | ±0 | ±0% | 192,100 |
2020/09/07 | 2,310 | 2,464 | 2,212 | 2,281 | -8 | -0.3% | 508,400 |
2020/09/04 | 2,136 | 2,386 | 2,113 | 2,289 | +88 | +4% | 509,000 |
2020/09/03 | 2,176 | 2,229 | 2,136 | 2,201 | +25 | +1.1% | 200,500 |
2020/09/02 | 2,103 | 2,186 | 2,095 | 2,176 | +76 | +3.6% | 202,400 |
2020/09/01 | 2,084 | 2,174 | 2,058 | 2,100 | -18 | -0.8% | 196,700 |
2020/08/31 | 2,037 | 2,168 | 2,021 | 2,118 | +121 | +6.1% | 256,800 |
2020/08/28 | 2,100 | 2,110 | 1,878 | 1,997 | -123 | -5.8% | 282,700 |
2020/08/27 | 2,156 | 2,169 | 2,024 | 2,120 | -38 | -1.8% | 224,300 |
2020/08/26 | 2,165 | 2,231 | 2,130 | 2,158 | +9 | +0.4% | 132,800 |
2020/08/25 | 2,157 | 2,211 | 2,082 | 2,149 | -12 | -0.6% | 231,600 |
2020/08/24 | 2,100 | 2,171 | 2,070 | 2,161 | +50 | +2.4% | 164,200 |
2020/08/21 | 1,980 | 2,192 | 1,980 | 2,111 | +171 | +8.8% | 508,100 |
2020/08/20 | 1,919 | 2,028 | 1,905 | 1,940 | +11 | +0.6% | 228,600 |
2020/08/19 | 1,932 | 1,943 | 1,879 | 1,929 | +2 | +0.1% | 98,400 |
2020/08/18 | 1,816 | 1,947 | 1,810 | 1,927 | +126 | +7% | 279,600 |
2020/08/17 | 1,901 | 1,909 | 1,782 | 1,801 | -139 | -7.2% | 272,300 |
2020/08/14 | 1,875 | 1,976 | 1,852 | 1,940 | +84 | +4.5% | 267,100 |
2020/08/13 | 1,830 | 1,875 | 1,796 | 1,856 | +46 | +2.5% | 129,400 |
2020/08/12 | 1,830 | 1,849 | 1,782 | 1,810 | -28 | -1.5% | 79,700 |
2020/08/11 | 1,770 | 1,840 | 1,744 | 1,838 | +77 | +4.4% | 92,100 |
2020/08/07 | 1,708 | 1,784 | 1,708 | 1,761 | +53 | +3.1% | 82,900 |
2020/08/06 | 1,847 | 1,847 | 1,703 | 1,708 | -107 | -5.9% | 161,600 |
2020/08/05 | 1,805 | 1,846 | 1,766 | 1,815 | +12 | +0.7% | 89,400 |
2020/08/04 | 1,735 | 1,827 | 1,730 | 1,803 | +86 | +5% | 120,600 |
2020/08/03 | 1,626 | 1,744 | 1,625 | 1,717 | +91 | +5.6% | 82,400 |
2020/07/31 | 1,678 | 1,735 | 1,616 | 1,626 | -61 | -3.6% | 119,100 |
2020/07/30 | 1,679 | 1,699 | 1,609 | 1,687 | +19 | +1.1% | 71,400 |
2020/07/29 | 1,648 | 1,692 | 1,615 | 1,668 | +42 | +2.6% | 101,700 |
2020/07/28 | 1,654 | 1,694 | 1,550 | 1,626 | -21 | -1.3% | 240,700 |
1151~
1200
件表示中 / 1631件
類似銘柄と比較する
現在ご覧いただいている「DELTA-P」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
DELTA-P | 62,600円 | - | - | 0.00% | - | 22.15倍 |
|
創薬ベンチャー。既存の抗がん物質を組み合わせて安全性と有効性を高めた抗がん剤を開発 |
モダリス | 8,500円 | - | - | 0.00% | - | 1.81倍 |
|
遺伝子治療薬の創薬ベンチャー、DNA切断しないエピゲノム編集に強み。研究開発中心は米国 |
OTS | 2,300円 | +33.3% | - | 0.00% | - | 9.62倍 |
|
がん治療ワクチン創薬ベンチャー。大手製薬と開発提携。東大医科研発。会社計画は非開示 |
クリングル | 88,300円 | +240.0% | - | 0.00% | - | 3.81倍 |
|
阪大発創薬ベンチャー。細胞増殖等機能持つHGFタンパク利用した難治性疾患治療薬を開発 |
カルナバイオ | 32,000円 | +13.5% | - | 0.00% | - | 2.47倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
市場注目の銘柄
チャート関連のコラム